Abstract
In the Western world, endometrial carcinoma is the most common malignant tumor of the female genital tract. The annual incidence has been estimated at 10–20 per 100,000 women. Two clinicopathological variants are recognized: the estrogen-related (type I, endometrioid) and the nonestrogen-related (type II, nonendometrioid). The clinicopathological differences are paralleled by specific genetic alterations, with type I showing microsatellite instability and mutations in PTEN, PIK3CA, K-RAS, andCTNNB1 (b-catenin), and type II exhibiting p53 mutations and chromosomal instability. Women with hereditary nonpolyposis colorectal carcinoma (HNPCC) have germline mutations in one of the DNA mismatch repair genes and frequently develop endometrioid endometrial carcinomas. Some nonendometrioid carcinomas probably arise from preexisting endometrioid carcinomas as a result of tumor progression and, not surprisingly, some tumors exhibit combined or mixed features at the clinical, pathological, and molecular levels. In endometrial carcinomas, apoptosis–resistance may play a role in tumor progression. Understanding pathogenesis at the molecular level is essential in identifying biomarkers for successful targeted therapies. This chapter reviews the genetic changes of endometrial carcinogenesis in the light of morphological features of the tumors and their precursors.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Castilla MÁ, Moreno-Bueno G, Romero-Pérez L, et al. Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. J Pathol. 2011;223:72–80.
Catasus L, Gallardo A, Cuatrecasas M, et al. PIK3CA mutations in the kinase domain (exon 20) of uterine endometrioid adenocarcinomas are associated with adverse prognostic parameters. Mod Pathol. 2008;21:131–9.
Catasus L, Gallardo A, Cuatrecasas M, et al. Concomitant PI3K/AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Mod Pathol. 2009a;22:522–9.
Catasus L, Gallardo A, Prat J. Molecular genetics of endometrial carcinoma. Diagn Histopathol. 2009b;15:554–63.
Catasus L, D’Angelo E, Pons C, et al. Expression profiling of 22 genes involved in the PI3K-AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations. Mod Pathol. 2010;23:694–702.
Cervello I, Mirantes C, Santamaria X, et al. Stem cells in human endometrium and endometrial carcinoma. Int J Gynecol Pathol. 2011;30:317–27.
Llobet D, Eritja N, Domingo M, et al. KSR1 is overexpressed in endometrial carcinoma and regulates proliferation and TRAIL-induced apoptosis by modulating FLIP levels. Am J Pathol. 2011;178:1529–43.
Montserrat N, Mozos A, Llobet D, et al. Epithelial to mesenchymal transition in early stage endometrioid endometrial carcinoma. Hum Pathol. 2011;43:632–43.
Ortega E, Marti RM, Yeramian A, et al. Target therapies in gynaecologic cancers and melanoma. Semin Diagn Pathol. 2008;25:262–73.
Prat J, Gallardo A, Cuatrecasas M, Catasús L. Endometrial carcinoma: pathology and genetics. Pathology. 2007;39(1):72–87.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Matias-Guiu, X., Prat, J. (2013). Molecular Pathology of Endometrial Cancer. In: Cheng, L., Eble, J. (eds) Molecular Surgical Pathology. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-4900-3_8
Download citation
DOI: https://doi.org/10.1007/978-1-4614-4900-3_8
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-4899-0
Online ISBN: 978-1-4614-4900-3
eBook Packages: MedicineMedicine (R0)